Insulin - NPH (Vetsulin/Caninsulin)

Insulin NPH, marketed under the brand names Vetsulin in the United States and Caninsulin internationally, represents the gold standard treatment for diabetes mellitus in dogs. This intermediate-acting porcine-origin insulin is specifically formulated and FDA-approved for veterinary use in canines, making it the first-choice insulin therapy recommended by most veterinary endocrinologists. Vetsulin has earned its position as the preferred insulin for diabetic dogs due to its reliable action profile, consistent manufacturing standards, and extensive safety data accumulated over decades of clinical use in veterinary medicine.

The mechanism of action of NPH insulin mirrors that of naturally occurring insulin produced by the pancreatic beta cells. When administered subcutaneously, Vetsulin facilitates the uptake of glucose from the bloodstream into cells throughout the body, particularly muscle and fat cells, while simultaneously inhibiting glucose production by the liver. The NPH formulation contains protamine, a protein that complexes with insulin to slow its absorption and extend its duration of action. This results in a peak effect occurring approximately four to eight hours after injection, with glucose-lowering activity lasting roughly eight to fourteen hours in most dogs, though individual variation exists.

Vetsulin is available as an injectable suspension in a concentration of 40 units per milliliter (U-40), which differs from the U-100 concentration commonly used in human insulin products. This distinction is critically important, as using incorrect syringes can result in dangerous dosing errors. The medication requires twice-daily subcutaneous injection for most diabetic dogs, typically administered at the time of feeding to coordinate insulin activity with glucose absorption from meals. The suspension must be gently mixed before each use to ensure uniform distribution of insulin particles, as improper mixing can lead to inconsistent dosing.

The overall safety profile of Vetsulin in dogs is well-established through extensive clinical trials and post-market surveillance. When used according to veterinary instructions with appropriate monitoring, most diabetic dogs achieve good glycemic control with minimal adverse effects. However, successful diabetes management requires commitment from pet owners to consistent dosing schedules, proper injection technique, dietary management, and regular veterinary monitoring. The variation in insulin requirements among individual dogs underscores the importance of working closely with a veterinarian to determine the optimal dose, as factors including body weight, diet, exercise, concurrent illnesses, and individual metabolism all influence insulin needs.

The primary indication for Vetsulin or Caninsulin is the treatment of diabetes mellitus in dogs, a condition characterized by insufficient insulin production or inadequate cellular response to insulin. Canine diabetes most commonly presents as Type 1 or insulin-dependent diabetes, where the pancreatic beta cells have been destroyed or severely damaged, necessitating lifelong exogenous insulin therapy. This condition affects approximately one in every 300 dogs, with certain breeds demonstrating higher susceptibility. Vetsulin serves as the cornerstone of treatment for these patients, replacing the insulin their bodies can no longer produce adequately and enabling proper glucose metabolism.

Diabetic dogs typically present with classic clinical signs including increased thirst and urination, weight loss despite increased appetite, and lethargy. Without treatment, diabetes progresses to diabetic ketoacidosis, a life-threatening emergency. Vetsulin therapy aims to eliminate these clinical signs, stabilize blood glucose levels within an acceptable range, prevent acute complications like hypoglycemia and ketoacidosis, and maintain quality of life. The goal is not necessarily to achieve perfect blood glucose control as in human diabetic management, but rather to keep glucose levels low enough to prevent symptoms while avoiding dangerous hypoglycemic episodes.

Secondary uses of NPH insulin in dogs include management of diabetes that develops secondary to other conditions. Pancreatitis, particularly chronic or severe acute pancreatitis, can damage insulin-producing cells and result in diabetes requiring insulin therapy. Similarly, dogs receiving long-term corticosteroid therapy or those with hyperadrenocorticism (Cushing's disease) may develop steroid-induced or secondary diabetes that requires insulin management. In some cases, addressing the underlying condition may reduce or eliminate the need for insulin, but many dogs require ongoing therapy. Vetsulin provides reliable glycemic control for these varied presentations of canine diabetes.

In clinical practice, Vetsulin is also used for diabetic dogs transitioning from other insulin types or those requiring adjustment from human insulin formulations that may not provide optimal control. Some dogs initially started on human insulin preparations may achieve better regulation when switched to this veterinary-specific product, as its pharmacokinetic profile is optimized for canine physiology. Additionally, dogs experiencing difficulty with longer-acting insulins or those requiring more flexible dosing schedules may benefit from the intermediate-acting profile of NPH insulin.

Veterinarians select Vetsulin as first-line therapy for newly diagnosed diabetic dogs due to its FDA approval status, established safety record, and predictable action profile in canines. The decision to use this insulin over alternatives considers factors including the individual dog's lifestyle, the owner's ability to administer twice-daily injections, concurrent health conditions, and financial considerations. For most uncomplicated diabetic dogs, Vetsulin provides an effective, safe, and practical option for lifelong diabetes management when combined with appropriate dietary modification and regular monitoring.

Dosing of Vetsulin must be individualized for each diabetic dog under direct veterinary supervision, as insulin requirements vary significantly based on body weight, severity of diabetes, diet, activity level, and concurrent health conditions. The typical starting dose for newly diagnosed diabetic dogs ranges from 0.25 to 0.5 units per kilogram of body weight, administered subcutaneously twice daily. However, this represents only an initial starting point, and most dogs require careful dose adjustments over several weeks to months to achieve optimal glycemic control. Your veterinarian will determine the appropriate starting dose and guide all subsequent modifications based on clinical response and monitoring results.

The standard dosing protocol involves twice-daily injections given approximately twelve hours apart, with each injection administered at the time of feeding. This coordination between insulin administration and meals is essential because insulin activity should coincide with the absorption of glucose from food. Most veterinarians recommend feeding a consistent diet divided into two equal meals, with the insulin injection given immediately before or after eating. Some dogs may require slight modifications to this schedule based on their individual glucose curves and lifestyle factors, but consistency in timing remains paramount for stable glycemic control.

Treatment duration for diabetes mellitus in dogs is typically lifelong, as most canine diabetics have permanent pancreatic beta cell destruction and cannot produce sufficient insulin independently. Rare cases of transient diabetes, particularly those induced by hormones during diestrus in intact female dogs, may resolve with spaying or other interventions. However, owners should prepare for ongoing daily insulin therapy as the standard expectation. Regular veterinary rechecks, initially frequent during the stabilization period and then every three to six months once stable, are essential for monitoring control and adjusting doses as needed over the dog's lifetime.

Administering Vetsulin requires proper technique to ensure consistent insulin delivery. Before each use, the vial should be gently rolled between the palms or inverted several times to resuspend the insulin particles evenly, as Vetsulin is a suspension that settles upon standing. Vigorous shaking should be avoided as it can damage the insulin molecules and create air bubbles. Using U-40 insulin syringes specifically designed for veterinary insulin, draw up the prescribed dose while avoiding air bubbles. The injection is given subcutaneously, typically in the scruff of the neck or along the side of the chest, rotating injection sites to prevent tissue changes. The skin should be gently pinched to create a tent, and the needle inserted at a forty-five-degree angle.

If a dose of Vetsulin is missed, owners should not attempt to give a double dose at the next scheduled time, as this significantly increases the risk of dangerous hypoglycemia. For missed morning doses discovered within a few hours, contact your veterinarian for guidance on whether to give a reduced dose or skip to the evening injection. If an evening dose is missed, it is generally safer to wait until the next morning's scheduled dose. Establishing a consistent routine and using reminders can help prevent missed doses. If you are unsure whether a full dose was administered due to the dog moving during injection, do not give additional insulin; instead, monitor for signs of high blood sugar and resume normal dosing at the next scheduled time.

Completing the prescribed treatment regimen and maintaining consistency are fundamental to successful diabetes management. Sudden discontinuation of insulin therapy will result in rapid return of hyperglycemia and clinical signs, potentially progressing to diabetic ketoacidosis. Even when a dog appears to be doing well, insulin therapy should never be stopped without veterinary guidance. Some dogs may eventually require dose reductions if underlying conditions resolve, but this determination must be made through proper monitoring including blood glucose curves and fructosamine levels rather than based solely on clinical appearance.

Vetsulin is generally well-tolerated by diabetic dogs when administered at appropriate doses with proper monitoring. The most significant concern during insulin therapy is hypoglycemia, which occurs when blood glucose levels drop too low. This is not technically a side effect of the insulin itself but rather a consequence of the insulin dose exceeding the body's glucose needs at that time. Risk factors for hypoglycemia include insulin overdose, missed or reduced meals, increased exercise, and concurrent illness affecting appetite. Owners of diabetic dogs must be thoroughly educated about recognizing and responding to hypoglycemic episodes.

Common mild effects observed during initial insulin therapy include transient changes in appetite and energy levels as the body adjusts to improved glucose regulation. Some dogs may experience increased appetite initially as cells begin receiving adequate glucose. Mild lethargy may occur as blood sugar levels normalize, particularly in dogs who had become accustomed to running at chronically elevated glucose levels. These effects typically resolve within the first few weeks of therapy as the dog's metabolism adjusts. Local injection site reactions, including minor swelling, redness, or hair loss at injection sites, occasionally occur but are generally mild and self-limiting with proper rotation of injection locations.

Moderate side effects requiring veterinary attention include signs of inadequate glycemic control or insulin resistance. Persistent polyuria, polydipsia, and weight loss despite insulin therapy suggest the need for dose adjustment or investigation of concurrent conditions interfering with insulin action. Somogyi rebound, also known as insulin-induced hyperglycemia, occurs when an excessive insulin dose causes hypoglycemia followed by a compensatory surge in blood glucose. This phenomenon can make diabetes appear uncontrolled when the actual problem is too much rather than too little insulin. Regular glucose curve monitoring helps differentiate between true insulin resistance and Somogyi effect.

Serious side effects requiring immediate veterinary intervention primarily relate to hypoglycemia. Signs of low blood sugar in dogs include weakness, trembling, disorientation, stumbling, seizures, and loss of consciousness. If conscious, the dog should be offered food immediately or have corn syrup or honey rubbed on the gums. Unconscious dogs should not have anything placed in their mouths due to aspiration risk; instead, syrup can be rubbed on the gums while seeking emergency veterinary care. Severe or prolonged hypoglycemia can cause permanent brain damage or death if not treated promptly. Allergic reactions to insulin are rare but possible, manifesting as hives, facial swelling, or anaphylaxis.

Long-term use of insulin therapy has not been associated with significant organ toxicity or cumulative adverse effects when properly monitored. Some dogs develop antibodies against porcine insulin over time, which may affect insulin efficacy, though this is less common with Vetsulin than with some human insulin products due to the greater similarity between porcine and canine insulin. Lipodystrophy, or changes in subcutaneous fat at injection sites, can occur with repeated injections in the same location but is preventable with proper site rotation. Regular veterinary monitoring including physical examination, blood glucose assessment, and periodic fructosamine measurement helps identify and address any emerging concerns before they become serious problems.

Vetsulin should not be administered to dogs with known hypersensitivity to porcine insulin or any component of the formulation. While true insulin allergies are uncommon in dogs, any dog that has previously experienced an allergic reaction to porcine-origin insulin products should not receive Vetsulin. Signs of allergic reactions may include localized swelling at injection sites, hives, facial swelling, difficulty breathing, or anaphylaxis. Dogs with suspected insulin allergies may need alternative insulin types derived from different sources, though options are limited and require careful veterinary management. Complete disclosure of any previous adverse reactions to medications helps your veterinarian make safe prescribing decisions.

Administration of insulin during active hypoglycemia is absolutely contraindicated, as this would further lower already dangerously low blood glucose levels and could be fatal. Before each insulin injection, owners should confirm their dog has eaten or is willing to eat, as giving insulin to a dog that refuses food significantly increases hypoglycemia risk. Dogs experiencing vomiting, diarrhea, or other conditions affecting food intake should not receive their usual insulin dose without veterinary guidance. During acute illness, insulin requirements may fluctuate unpredictably, and sick day protocols should be established in advance with your veterinarian for these situations.

Certain concurrent medical conditions require careful consideration before initiating or continuing insulin therapy. Dogs with adrenal insufficiency (Addison's disease) may have altered glucose metabolism and insulin sensitivity requiring specialized management. Severe hepatic disease can impair glucose production and increase hypoglycemia risk. Dogs with insulinomas (insulin-producing tumors) may have erratic glucose levels that complicate exogenous insulin therapy. While these conditions do not absolutely preclude insulin use, they require heightened monitoring and potentially modified treatment approaches. Thorough diagnostic evaluation should precede insulin therapy to identify any underlying conditions that might complicate diabetes management.

Pregnancy and breeding considerations apply to Vetsulin use in dogs. While diabetes must be managed during pregnancy to protect both the mother and developing puppies, insulin requirements change dramatically throughout gestation and the postpartum period. Intact female dogs often experience insulin resistance during diestrus due to progesterone effects, and spaying is frequently recommended as part of diabetes management in female dogs. Breeding diabetic dogs is generally discouraged due to the hereditary component of canine diabetes and the management challenges during pregnancy. Lactating dogs have increased metabolic demands that affect insulin requirements. These complex scenarios require intensive veterinary management and monitoring far beyond routine diabetic care. Any owner considering breeding a diabetic dog should have thorough discussions with their veterinarian about the significant risks and challenges involved.

Managing a diabetic dog on insulin therapy requires careful consideration of all concurrent medications, supplements, and dietary factors, as many substances can affect blood glucose levels or insulin action. Pet owners must inform their veterinarian about every medication, supplement, and over-the-counter product their dog receives, including flea and tick preventatives, heartworm medications, joint supplements, and any other treatments. This comprehensive disclosure enables safe prescribing and appropriate monitoring adjustments when potentially interacting substances are necessary.

Corticosteroids represent the most clinically significant drug class interaction with insulin therapy in dogs. Glucocorticoids such as prednisone, prednisolone, dexamethasone, and triamcinolone cause insulin resistance and elevate blood glucose levels through multiple mechanisms. Dogs receiving concurrent corticosteroid therapy typically require substantially higher insulin doses, often two to three times their baseline requirement, and may experience difficulty achieving stable glycemic control. When corticosteroid therapy is medically necessary in diabetic dogs, close monitoring with frequent glucose curves is essential, and insulin doses must be adjusted both when starting steroids and during tapering. Sudden discontinuation of steroids without corresponding insulin reduction can cause severe hypoglycemia. Other hormonal medications, including progestins and thyroid hormones, can also affect glucose metabolism and insulin requirements.

Several medication classes can potentiate the hypoglycemic effect of insulin, increasing the risk of low blood sugar episodes. Beta-blockers, while uncommonly used in dogs, can mask tachycardia that normally signals hypoglycemia and may prolong hypoglycemic episodes. Angiotensin-converting enzyme (ACE) inhibitors, frequently prescribed for canine heart disease, may enhance insulin sensitivity and necessitate dose reduction. Certain antibiotics, particularly fluoroquinolones, have been associated with blood glucose disturbances. Monoamine oxidase inhibitors and salicylates can also potentiate insulin effects. When these medications are necessary for concurrent conditions, enhanced monitoring and potential insulin dose adjustments are warranted.

Dietary factors and supplements can influence blood glucose control and insulin effectiveness in diabetic dogs. High-fiber diets are generally recommended for diabetic dogs as they slow glucose absorption and reduce postprandial glucose spikes, but sudden dietary changes can affect insulin requirements. Certain supplements including alpha-lipoic acid, chromium, and cinnamon have glucose-lowering properties that could potentiate insulin action. Fish oil supplements, commonly given for skin health or joint support, generally do not significantly impact glucose control but should still be disclosed. The timing of meals relative to insulin injection critically affects glucose dynamics, and any changes to feeding schedule or diet composition should be discussed with your veterinarian. Consistent feeding of the same amount and type of food at the same times daily helps maintain stable insulin requirements and predictable glucose patterns.

Successful management of a diabetic dog on Vetsulin requires careful attention to numerous precautions that help ensure safe and effective therapy. Accurate dosing is paramount, as insulin has a narrow therapeutic window where too little results in persistent hyperglycemia and diabetic symptoms while too much causes potentially fatal hypoglycemia. Always use U-40 insulin syringes specifically designed for veterinary U-40 insulin concentrations; using standard U-100 syringes designed for human insulin will result in significant dosing errors. Draw up insulin doses carefully in good lighting, verify the dose before injection, and maintain consistency in technique to ensure accurate delivery.

Breed-specific considerations exist for diabetes management, though the condition affects dogs of all breeds. Certain breeds demonstrate higher diabetes prevalence, including Samoyeds, Australian Terriers, Miniature Schnauzers, Miniature and Toy Poodles, Pugs, and Bichon Frises. These predisposed breeds may benefit from earlier screening and intervention. While the MDR1 gene mutation common in herding breeds does not directly affect insulin therapy, diabetic dogs of these breeds receiving other medications should be evaluated for potential interactions. Giant breeds may require large insulin volumes that necessitate splitting injections between two sites, while toy breeds require precise measurement of small doses where even minor inaccuracies represent significant percentage errors.

Household safety precautions are essential when managing a diabetic pet. Insulin vials and syringes should be stored safely away from children and other pets. Used syringes should be disposed of in appropriate sharps containers rather than regular household trash. Family members involved in the dog's care should be trained in proper insulin administration, recognition of hypoglycemic signs, and emergency response procedures. In multi-pet households, diabetic dogs should be fed separately to ensure they consume their full meal before insulin administration, as other pets stealing food can result in inadequate glucose intake to match the insulin dose.

Monitoring requirements during Vetsulin therapy include regular assessment of both clinical signs and laboratory parameters. Owners should track their dog's water intake, urination frequency, appetite, body weight, and energy levels, reporting significant changes to their veterinarian. Blood glucose curves, performed either in the hospital or through at-home monitoring with proper training, help assess glycemic control and guide dose adjustments. Fructosamine measurement provides information about average blood glucose over the preceding two to three weeks. Urine glucose monitoring, while less precise than blood glucose, can serve as a simple at-home screening tool between veterinary visits. Regular physical examinations help identify concurrent conditions that might affect diabetes control.

Special populations of dogs require additional considerations during insulin therapy. Geriatric dogs may have concurrent conditions affecting kidney or liver function that alter insulin metabolism and increase complication risks. Puppies rarely develop diabetes, but those affected require careful management due to their rapid growth and changing metabolic needs. Dogs with concurrent illnesses such as urinary tract infections, dental disease, or inflammatory conditions may experience insulin resistance that improves once the underlying condition is addressed. Working or performance dogs need insulin and feeding schedules adjusted around their activity patterns, as exercise significantly lowers blood glucose. Owners traveling with diabetic dogs must plan for insulin storage, feeding schedules across time zones, and emergency veterinary access at their destination.

Proper storage of Vetsulin is essential for maintaining insulin potency and ensuring consistent therapeutic effect. Unopened vials should be stored refrigerated between 36°F and 46°F (2°C to 8°C), protected from light, and kept in their original carton until use. Insulin should never be frozen, as freezing destroys the insulin molecules and renders the product ineffective; any vial that has been frozen should be discarded. Similarly, insulin should not be exposed to excessive heat, including being left in a car during warm weather or placed near heating sources. Before first use, check the expiration date on the vial and do not use if expired.

Once opened, Vetsulin vials have a limited shelf life and require specific handling. According to manufacturer guidelines, opened vials of Vetsulin should be discarded after 42 days (six weeks), regardless of how much insulin remains, as potency may decline beyond this period. Some veterinarians recommend even shorter timeframes for optimal efficacy. Opened vials should be kept refrigerated between uses. Before each use, the vial should be gently rolled between the palms or inverted several times to resuspend the insulin particles uniformly. The suspension should appear uniformly milky white after mixing; if it appears clumped, discolored, or contains particles that do not resuspend, the vial should be discarded. Never shake insulin vigorously, as this can damage the molecules and create foam that interferes with accurate dosing.

Safe handling and disposal of insulin supplies protects both household members and the environment. Always use a new syringe for each injection to prevent contamination of the insulin vial and ensure sharp, comfortable needle insertion. Used syringes and needles should be placed immediately in a designated sharps container approved for medical waste. When the sharps container is full, it should be disposed of according to local regulations, which may include designated drop-off sites, mail-back programs, or special trash collection. Never throw loose needles in household trash or recycling. Keep all insulin supplies, including vials, syringes, and sharps containers, out of reach of children and pets. Dogs may be attracted to the smell of insulin vials and could chew on them, creating both a safety hazard and loss of medication. Establish a dedicated, secure storage location for all diabetes management supplies to maintain organization and safety.

While diabetes mellitus can affect dogs of any breed, certain breeds demonstrate significantly higher predisposition to developing this condition, making breed awareness an important component of diabetes prevention and management. Breeds with elevated diabetes risk include Samoyeds, Australian Terriers, Miniature Schnauzers, Miniature and Toy Poodles, Pugs, Bichon Frises, Keeshonden, and Fox Terriers. Owners of predisposed breeds should be particularly vigilant for early signs of diabetes, including increased thirst, frequent urination, weight loss despite good appetite, and lethargy. Early detection and intervention generally improve long-term outcomes and may reduce the required insulin dose.

The MDR1 (ABCB1) gene mutation common in herding breeds does not directly affect insulin therapy, as insulin is not a substrate for the P-glycoprotein transporter affected by this mutation. However, diabetic dogs from MDR1-affected breeds including Collies, Australian Shepherds, Shetland Sheepdogs, and related breeds may require concurrent medications that are affected by this mutation. Veterinarians managing diabetic herding breed dogs should screen for MDR1 status and consider drug interactions carefully when prescribing additional medications. Conditions commonly requiring treatment alongside diabetes, such as infections or pain, may necessitate modified drug selection in MDR1-positive dogs to avoid potentially dangerous interactions.

Size variation among dog breeds creates important practical considerations for insulin therapy. Giant breeds such as Great Danes, Mastiffs, and Saint Bernards may require insulin doses that exceed the volume comfortably administered at a single injection site, necessitating splitting the dose between two locations. Their larger body mass can also mean that blood glucose patterns differ from smaller dogs, potentially affecting the timing of insulin activity. Conversely, toy breeds including Chihuahuas, Yorkshire Terriers, and Maltese require extremely precise insulin measurement where even one-unit dosing errors represent a large percentage of the total dose. Specialized low-dose syringes with half-unit markings may be necessary for accurate dosing in very small dogs. Weight accuracy is critical for all dogs but especially for those at the extremes of the size spectrum.

Age-related factors intersect with breed considerations in diabetic dogs. Smaller breeds generally live longer and may have more years of diabetes management ahead of them when diagnosed, making early achievement of stable control particularly valuable. Larger and giant breeds have shorter lifespans and may develop diabetes later relative to their expected longevity. Puppies of any breed rarely develop diabetes, but those that do require specialized pediatric management accounting for rapid growth and changing metabolic needs. Senior dogs commonly have concurrent conditions such as kidney disease, heart disease, or arthritis that complicate diabetes management and require integrated treatment planning. Breed-specific predispositions to these concurrent conditions should inform comprehensive care planning for older diabetic dogs.

Several alternative insulin types may be considered for diabetic dogs when Vetsulin does not provide adequate control or when specific patient factors favor different options. Insulin glargine (Lantus) is a long-acting human insulin analog that some veterinarians prescribe off-label for dogs, particularly those with difficulty achieving stable control on intermediate-acting insulins. Insulin detemir (Levemir) is another long-acting option occasionally used in canine patients. NPH insulin formulated for human use (Humulin N, Novolin N) contains the same insulin type as Vetsulin but at U-100 concentration, requiring careful attention to appropriate syringe selection. Regular insulin (short-acting) may be used in hospital settings for diabetic ketoacidosis but is not appropriate for routine home management due to its short duration of action.

Different therapeutic approaches may be considered for specific diabetic presentations or when insulin alone provides inadequate control. Oral hypoglycemic agents such as glipizide, commonly used in diabetic cats, have shown limited efficacy in dogs and are not typically recommended for canine diabetes management. However, research continues into adjunctive therapies that might enhance insulin sensitivity or reduce insulin requirements. Dogs with diabetes secondary to hyperadrenocorticism may benefit from treatment of the underlying Cushing's disease, which can improve insulin sensitivity and reduce required doses. Intact female dogs with diabetes related to diestrus hormones often experience significant improvement or resolution following ovariohysterectomy (spaying).

Complementary supportive care plays an important role alongside insulin therapy in comprehensive diabetes management. Dietary modification forms a cornerstone of diabetic dog management, with most veterinarians recommending consistent high-fiber, complex-carbohydrate diets fed at the same times daily. Prescription diabetic diets from major pet food manufacturers are formulated to support stable glucose levels. Weight management is critical, as obesity worsens insulin resistance while excessive weight loss indicates inadequate glycemic control. Regular moderate exercise helps improve insulin sensitivity but must be balanced with appropriate feeding and insulin timing to prevent hypoglycemia. Dental care, prompt treatment of infections, and management of concurrent conditions all contribute to stable diabetes control. Owners should never attempt to substitute alternative therapies for prescribed insulin without veterinary guidance, as uncontrolled diabetes rapidly progresses to life-threatening diabetic ketoacidosis.